Therapeutic Strategies for the Treatment of Ocular Surface Disorders


Ocular surface disease (OSD) is a very common disorder, which affects millions of Americans (Online access: ). OSD affects the cornea, conjunctiva, eye lids, meibomian glands, or pre-ocular tear film. The dysfunction of these components can result in damage to the ocular surface, which necessitates rapid recognition and intervention to prevent patients from suffering permanent damage. Prompt diagnosis and treatment is crucial to successfully managing OSD and emphasizes the need for educational interventions to reach the ultimate goal of improving patient care. This CME activity will bring clinicians up to date with guidelines, as well as the most effective techniques to integrate these guidelines when making individualized treatment plans for patients. In addition current clinical trial data of emerging and available therapies will be discussed to ensure the more efficient treatment is provided to patients. In addition, practical strategies to apply this knowledge in practice will be provided to ensure optimal care for every patient with OSD.

This CME Multimedia Activity is also available through the website of American Journal of Ophthalmology ( ). Click on the Multimedia button in the navigation bar for full access.


This enduring material has been peer-reviewed and approved by the American Journal of Ophthalmology.

This activity is co-sponsored by the Elsevier Office of Continuing Medical Education and Academic CME.

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Eric D. Donnenfeld, MD is a consultant/advisor for Abbott Medical Optics Inc. (AMO), Alcon Laboratories, Inc; AqueSys Inc., Bausch + Lomb, CRST, Elenza, Inc. Glaukos, Kala Pharmaceuticals, Inc, LacriPen, LenSx, Mati Therapeutics, Merck & Co., Inc.; Mimetogen Pharmaceuticals, NovaBay Pharmaceuticals, Inc., Odyssey Pharmaceuticals, Inc., Pfizer, Inc., PRN Pharmaceuticals, QLT Inc., ReSearch Pharmaceutical Services, SARcode Bioscience Inc., Strathspey Crown, LLC, TearLab Corp., TearScience, TLC Laser Centers, TrueVision Systems, and WaveTec Vision Systems, Inc.

Christopher E. Starr, MD is a consultant/advisor for Allergan, Inc., Bausch & Lomb, NicOx and Topigen Pharmaceuticals Inc., ReSearch Pharmaceutical Services; and TearLab Corp. He is on the Speaker’s Bureau of Alcon Laboratories, Inc., Allergan, Inc., Bausch & Lomb, and TearLab Corp. He has stock ownership in TearLab Corp.

Henry Perry, MD is a consultant/advisor for Alcon Laboratories, Inc. and Allergan, Inc.

Non-faculty: Sandy Breslow; Jill McNair; Katelynn Steck; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Jaimie Kelly; and Tania Dickson, PhD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Funding: This activity has been supported by an independent educational grant from Alcon Research, Ltd. and Bausch + Lomb.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jan 6, 2017 | Posted by in OPHTHALMOLOGY | Comments Off on Therapeutic Strategies for the Treatment of Ocular Surface Disorders

Full access? Get Clinical Tree

Get Clinical Tree app for offline access